Vaccination against hepatitis B virus (HBV) in HIV-1-infected patients with isolated anti-HBV Core antibody: The ANRS HB EP03 CISOVAC prospective study

Journal of Infectious Diseases

Volumn 213, Issue 11, 2016, Pages 1735-1742

  Piroth, Lionel ^a   Launay, Odile ^b   Michel, Marie Louise ^c   Bourredjem, Abderrahmane ^d   Miailhes, Patrick ^e   Ajana, Faiza ^f   Chirouze, Catherine ^g   Zucman, David ^h   Wendling, Marie Josee ⁱ   Nazzal, Dani ^b   Carrat, Fabrice ^j,k,l   Rey, David ⁱ   Binquet, Christine ^d  

^a UNIV BOURGOGNE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f Service des Maladies Infectieuses   (France)

^g UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^h FOCH HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

HBV; HIV; Immunology; Isolated anti HBc; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADULT; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; VACCINATION; VIRUS LOAD; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; VACCINE IMMUNOGENICITY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGENICITY, VACCINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINES, SYNTHETIC;

EID: 84966704136     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw011     Document Type: Article

References (30)

1. Treitinger A, Spada C, Silva EL, et al. Prevalence of serologic markers of HBV and HCV infection in HIV-1 seropositive patients in Florianopolis, Brazil. Braz J Infect Dis 1999; 3:1-5.
2. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991; 4:416-20.
3. Francisci D, Baldelli F, Papili R, Stagni G, Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995; 11:123-6.
4. Ockenga J, Tillmann H, Trautwein C, Stoll M, Manns M, Schmidt R. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27:18-24.
5. Landrum ML, Roediger MP, Fieberg AM, et al. Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: a rare opportunistic illness. J Med Virol 2011; 83:1537-43.
6. KhamduangW, Ngo-Giang-Huong N, Gaudy-Graffin C, et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis 2013; 56:1704-12.
7. Witt MD, Lewis RJ, Rieg G, Seaberg EC, Rinaldo CR, Thio CL. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and-uninfected men in the multicenter AIDS cohort study. Clin Infect Dis 2013; 56:606-12.
8. Pallawela SN, Sonnex C, Mabayoje D, et al. Positive hepatitis B virus core antibody in HIV infection-false positive or evidence of previous infection? J Med Virol 2015; 87:208-12.
9. Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002; 36:681-6.
10. Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai 2006; 89:2028-34.
11. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435-41.
12. Launay O, Masurel J, Servant-Delmas A, et al. High levels of serum hepatitis B virus DNA in patients with 'anti-HBc alone': role of HBsAg mutants. J Viral Hepat 2011; 18:721-9.
13. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32:102-12.
14. El Chaar M, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010; 52:1600-10.
15. Wang Q, Sachse P, Semmo M, et al. T-And B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients. J Viral Hepat 2015; 22:1068-78.
16. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195:1437-42.
17. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81:441-5.
18. Sun HY, Lee HC, Liu CE, et al. Factors associated with isolated anti-hepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat 2010; 17:578-87.
19. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-9.
20. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIVpositive patients: case series and review of the literature. AIDS 2007; 21:771-4.
21. French AL, Lin MY, Evans CT, et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis 2009; 49:148-54.
22. Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis 2010; 50:1184-6.
23. Kaech C, Pache I, Burgisser P, Elzi L, Darling KE, Cavassini M. Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen. J Infect 2012; 65:157-64.
24. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305:1432-40.
25. Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015; 15:1283-91.
26. Nazzal D, Felin A, Godon O, et al. Defect in B cell maturation and BAFFR expression in HIV-infected patients with isolated anti-hepatitis B core (a-HBc) antibodies. In: 30 years of HIV science. Paris, France, 2013.
27. Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228:1195-9.
28. Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T-And B-cell immune response in non-And low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine 2014; 32:5077-82.
29. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24:572-7.
30. Heuft MM, Houba SM, van den Berk GE, et al. Protective effect of hepatitis B virus-Active antiretroviral therapy against primary hepatitis B virus infection. AIDS 2014; 28:999-1005.